{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Hims & Hers Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Hims & Hers Health, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 74 and a price-to-book value of 22.96. The company boasts a strong return on capital employed at 50.18% and a year-to-date return of 101.74%, amid significant stock volatility.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of October 24, 2025, Hims & Hers Health, Inc. is fairly valued with a P/E ratio of 74 and strong year-to-date returns of 101.74%, despite recent underperformance against the S&P 500.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of October 24, 2025, Hims & Hers Health, Inc. is fairly valued with a P/E ratio of 74 and strong returns, despite high valuation ratios compared to peers, indicating efficient capital utilization but warranting caution.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of October 17, 2025, Hims & Hers Health, Inc. is considered overvalued with high P/E, price-to-book, and EV to EBITDA ratios, despite strong recent performance, indicating that its current stock price may not be sustainable.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of October 17, 2025, Hims & Hers Health, Inc. is considered overvalued with a P/E ratio of 74 and a valuation grade of "expensive," despite a strong year-to-date return of 105.87%, indicating potential challenges in sustaining performance.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of October 17, 2025, Hims & Hers Health, Inc. is considered overvalued with a valuation grade of "expensive," reflected by high ratios such as a P/E of 74 and an EV to EBITDA of 89.10, despite a strong annual return of 130.89%.
Hims & Hers Health, Inc. Experiences Evaluation Revision Amid Strong Market Performance
Hims & Hers Health, Inc. has recently revised its evaluation amid current market dynamics. The stock has shown impressive performance over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and bearish trends, while the company continues to demonstrate strong growth potential.
Is Hims & Hers Health, Inc. technically bullish or bearish?
As of October 10, 2025, Hims & Hers Health, Inc. shows a mildly bullish trend with mixed technical signals, outperforming the S&P 500 significantly year-to-date and over the past year.
Is Hims & Hers Health, Inc. technically bullish or bearish?
As of October 10, 2025, Hims & Hers Health, Inc. has a mildly bullish technical trend, with daily moving averages and Bollinger Bands supporting this stance, despite a mildly bearish MACD on the weekly chart.
Is Hims & Hers Health, Inc. technically bullish or bearish?
As of October 10, 2025, Hims & Hers Health, Inc. shows a mildly bullish trend with mixed technical indicators, including a bullish daily moving average and a year-to-date return of 123.12%, significantly outperforming the S&P 500's 11.41%.
Hims & Hers Health Hits Day Low of $52.51 Amid Price Pressure
Hims & Hers Health, Inc. saw a notable stock decline today, despite a strong performance over the past year, including a 206.71% increase. The company reported significant net profit growth and has maintained positive results for 13 consecutive quarters, reflecting its operational strength and high institutional ownership.
Is Hims & Hers Health, Inc. technically bullish or bearish?
As of September 12, 2025, Hims & Hers Health, Inc. shows a bullish technical trend, supported by daily moving averages and Bollinger Bands, despite mixed signals from MACD and KST, while significantly outperforming the S&P 500 with a year-to-date return of 132.42%.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of September 11, 2025, Hims & Hers Health, Inc. is considered overvalued with a valuation grade of expensive, reflected by a high P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10, despite outperforming the S&P 500 with a year-to-date return of 132.42%.
Hims & Hers Health Hits Day High with 11.62% Surge in Stock Price
Hims & Hers Health, Inc. has shown remarkable performance, achieving a 159.94% return over the past year and a 132.42% increase year-to-date. The company has reported consistent net profit growth and maintains a high institutional ownership rate, reflecting strong investor confidence and robust financial health.
Hims & Hers Health, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance
Hims & Hers Health, Inc. has recently revised its evaluation amid changing market dynamics. The company has achieved a remarkable 225.65% return over the past year, significantly outperforming the S&P 500. Its stock performance reflects resilience and adaptability within the competitive pharmaceuticals and biotechnology sector.
Hims & Hers Health Achieves 225.65% Return, Establishing It as a Multibagger Stock
Hims & Hers Health, Inc. has recently undergone a revision in its score, reflecting its impressive performance metrics and strong market position. The company has achieved significant net profit growth and maintained a robust operating cash flow, attracting substantial institutional interest. Despite minor fluctuations, Hims & Hers continues to demonstrate resilience in the market.
Is Hims & Hers Health, Inc. overvalued or undervalued?
As of May 8, 2025, Hims & Hers Health, Inc. is considered overvalued with a high P/E ratio of 74 and a recent stock performance that, despite a year-to-date return of 73.61%, has seen a significant drop of 29.78% in the past week, leading to a shift in its valuation grade from attractive to fair.
Is Hims & Hers Health, Inc. technically bullish or bearish?
As of May 1, 2025, the technical trend has shifted to bullish, supported by strong indicators like the MACD and KST, despite some mixed signals from Bollinger Bands and Dow Theory.
What does Hims & Hers Health, Inc. do?
Hims & Hers Health, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $586 million and a net profit of $49 million. Key metrics include a P/E ratio of 74.00 and a return on equity of 30.96%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
